Serina Therapeutics, Inc. (SER)
| Previous Close | 10.00 |
| Open | 9.62 |
| Bid | 5.00 x 1000 |
| Ask | 12.80 x 1000 |
| Day's Range | 9.00 - 9.62 |
| 52 Week Range | 9.00 - 35.71 |
| Volume | |
| Avg. Volume | 5,145 |
| Market Cap | 22.983M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireSerina Therapeutics Appoints Dr. Simba Gill as Executive Chairman
- Dr. Gill brings extensive leadership experience in transformative biotechnology platforms and drug development - HUNTSVILLE, AL, April 17, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (NYSE American: SER), a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM drug delivery technology today announced the appointment of Dr. Simba Gill as Executive Chairman. Serina’s proprietary POZ PlatformTM aims to develop and improve therapeutics across multiple mod
- GlobeNewswire
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol “SER” on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024; IND submission to the FDA for the initiation of a Phase I clinical trial planned for 2025 HUNTSVILLE, Ala., March 26, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics (NYSE American: SER), a clinical-stage biotechnology company developing a pipeline of therapies for the treatment of
